ProMIS Neurosciences, Inc trades with the ticker PMN on the TSX and is in the Biotechnology industry.
Overview
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Looking to invest in ProMIS Neurosciences, Inc? Our analysis brings in the key facts, competitor research and valuation metrics for you to make an informed decision.
Table of Contents
show
PMN.TO Stock Price and Key Stats
ETF Key Stats
Exchange: TSX
Market Cap : $51.476MM
PE Ratio:
Price: 1.86 (Updated: 3/12/2024 0:47:16)
ProMIS Neurosciences, Inc (PMN) vs Competitors in Biotechnology
Lets see how PMN.TO stacks up against others in the Biotechnology asset management industry. We have identified its main peers as:Aeterna Zentaris Inc, Aptose Biosciences Inc, BELLUS Health Inc, Fennec Pharmaceuticals Inc, IMV Inc
.Biotechnology Industry Comparisons
| Company | Market Cap ($MM) | P/E Ratio | EV/EBITDA | Dividend Yield |
|---|---|---|---|---|
| Aeterna Zentaris Inc (AEZS) | $12.674 | N/A | 1.709 | N/A% |
| Aptose Biosciences Inc (APS) | $33.927 | N/A | -0.231 | N/A% |
| BELLUS Health Inc (BLU) | $2,470.298 | N/A | -16.428 | 0.0% |
| Fennec Pharmaceuticals Inc (FRX) | $352.565 | N/A | -21.793 | N/A% |
| IMV Inc (IMV) | $13.117 | N/A | -0.843 | 0.0% |
EV/EBITDA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation, and Amortization – this ratio compares the value of a company, including debt, to the company’s cash earnings less non-cash expenses
Industry: companies that have a lot in common
Market Cap: Market Capitalization – the total value of all a corporation’s stock
N/A: Not Applicable or Not Available
P/E: Price-to-Earnings – this ratio relates a corporation’s share price to its earnings per share
Price: Stock Price – current value to buyers and sellers
Dividend Yield: Dividend or Distribution Yield
Comparisons within Biotechnology
- ProMIS Neurosciences, Inc (PMN) vs Aeterna Zentaris Inc (AEZS)
- PMN has higher EPS (-3.38 vs -6.47). PMN provides dividends, while AEZS does not. AEZS and PMN both have P/E’s under 0.
- ProMIS Neurosciences, Inc (PMN) vs Aptose Biosciences Inc (APS)
- PMN has higher EPS (-3.38 vs -10.45). PMN provides dividends, while APS does not. APS and PMN both have P/E’s under 0.
- ProMIS Neurosciences, Inc (PMN) vs BELLUS Health Inc (BLU)
- BLU has higher EPS (-0.96 vs -3.38). BLU has higher dividend yield (0.0% vs 0.0%). BLU and PMN both have P/E’s under 0.
- ProMIS Neurosciences, Inc (PMN) vs Fennec Pharmaceuticals Inc (FRX)
- FRX has higher EPS (-1.01 vs -3.38). PMN provides dividends, while FRX does not. FRX and PMN both have P/E’s under 0.
- ProMIS Neurosciences, Inc (PMN) vs IMV Inc (IMV)
- PMN has higher EPS (-3.38 vs -6.11). IMV has higher dividend yield (0.0% vs 0.0%). IMV and PMN both have P/E’s under 0.
Our Recommendation: Hold
Shows positive EPS growth from this year to next, suggesting improving profitability.
How to Buy PMN stock on the TSX
You can buy on pretty much any online brokerage in Canada, since it trades on the TSX. If you are looking for some easy options take a look at these two:| Image | Product Title | Features | Price |
|---|---|---|---|
Editor's Choice  |
| Get $25 Signup Bonus | |
Reliable Pick  |
| Get $50 Free Stock Trades |
